New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:25 EDTELN, MAT, VVUS, TSN, DELL, ALKS, MCK, GDOT, MRK, LTM, NFLX, CTRP, ADNCOn The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: Audience (ADNC), up 30%... Tyson Foods (TSN), up 3.3%... Ctrip.com (CTRP), up 8.5%... Green Dot (GDOT), up 6.5%... ALSO HIGHER: Dell (DELL), up 6% after Reuters says 'go private' deal may happen Monday... VIVUS (VVUS), up 5.7% after study published on weight loss drug improving cardiovascular disease risk factors... Netflix (NFLX), up 3.3% after Morgan Stanley raises price target on shares to $200... DOWN AFTER EARNINGS/GUIDANCE: Merck (MRK), down 2.9%... McKesson (MCK), down 2.1%... Mattel (MAT), down 1.7%... Life Time Fitness (LTM), down 16.4%... ALSO LOWER: Alkermes (ALKS), down 5.9% after Elan (ELN) to sell remaining stake, shares downgraded to Neutral at BofA Merrill Lynch.
News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Check below for free stories on DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 8, 2014
09:09 EDTCTRPOn The Fly: Pre-market Movers
HIGHER: BioScrip (BIOS), up 6.7% after stock was named as a stock pick and a potential takeover target by Oscar Schafer while speaking on CNBC... Nokia (NOK), up 5% after deal to sell substantially all of its Devices & Services business to Microsoft (MSFT) receives regulatory approval in China... Ctrip.com (CTRP), up 4.6% after Bloomberg said, citing sources, that the company is in talks with Baidu-controlled (BIDU) Qunar (QUNR) about a partnership or a potential merger... Plug Power (PLUG), up 4.6% after CEO discusses plan to expand fuel cells to trucks in interview... FireEye (FEYE), up 2.5% following upgrade at Wedbush... Twitter (TWTR), up 2% following initiation of coverage with a Buy rating at at Janney Capital... Nike (NKE), up 1.75% after upgraded at Stifel. LOWER: Gigamon (GIMO), down 23% after lowering revenue outlook, shares downgraded at Pacific Crest... LivePerson (LPSN), down 3% after announcing resignation of EVP, Worldside Sales, shares downgraded at Benchmark... Cisco (CSCO), down 0.5% following downgrade to Hold from Buy at Wunderlich.
09:00 EDTALKSAlkermes rises 7.4%
Alkermes is up 7.4%, or $3.03, to $44.13
07:47 EDTALKSAlkermes to host conference call
Subscribe for More Information
07:28 EDTNFLXFour Internet stocks attractive after pullbacks, says Stifel
Subscribe for More Information
07:22 EDTCTRPQunar, Ctrip.com in talks on potential merger, Bloomberg says
Chinese travel websites Qunar (QUNR) and Ctrip.com (CTRP) are in talks on a range of possibilities, from a partnership to a full merger, according to Bloomberg, citing two people with direct knowledge of the talks. Qunar, which went public last year in the U.S., is majority owned by Chinese search giant Baidu (BIDU), which recently had over 58% of voting power via its stake. Reference Link
07:04 EDTALKSAlkermes announces phase 3 'positive' results from aripiprazole lauroxil study
Alkermes announced "positive" topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale total scores at week 12, compared to placebo, which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application to the U.S. Food and Drug Administration in 3Q14. In addition to meeting the prespecified primary efficacy endpoint, the study also met the prespecified key secondary endpoint of improvement on the Clinical Global Impression-Improvement scale versus placebo at week 12. Aripiprazole lauroxil was generally well tolerated in the phase 3 study, and the safety profile of aripiprazole lauroxil was similar to that reported with oral aripiprazole. The most common adverse events in the study were insomnia, akathisia and headache. Alkermes will present data from the phase 3 study at an upcoming medical meeting and submit the results for publication in a peer-reviewed journal.
05:49 EDTCTRPStocks with implied volatility movement; CTRP GMCR
Subscribe for More Information
April 7, 2014
16:01 EDTNFLXOptions Update; April 7, 2014
Subscribe for More Information
10:00 EDTMATOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTNFLXOn The Fly: Analyst Upgrade Summary
Agios Pharmaceuticals (AGIO) upgraded to Overweight from Neutral at JPMorgan... Alcoa (AA) upgraded to Hold from Sell at Deutsche Bank... Align Technology (ALGN) upgraded to Outperform from Market Perform at Barrington... Analog Devices (ADI) upgraded to Neutral from Sell at Goldman... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Citigroup (C) upgraded to Neutral from Underweight at HSBC... Intel (INTC) upgraded to Outperform from Sector Perform at Pacific Crest... JetBlue (JBLU) upgraded to Neutral from Sell at Goldman... Kindred Healthcare (KND) upgraded to Outperform from Sector Perform at RBC Capital... Lennox (LII) upgraded to Outperform from Market Perform at Wells Fargo... Newmont Mining (NEM) upgraded to Hold from Sell at Deutsche Bank... PBF Energy (PBF) upgraded to Buy from Neutral at Citigroup... Renasant (RNST) upgraded to Outperform from Market Perform at Raymond James... Select Medical (SEM) upgraded to Outperform from Sector Perform at RBC Capital... Ultra Petroleum (UPL) upgraded to Outperform from Market Perform at Raymond James... Under Armour (UA) upgraded to Buy from Neutral at Sterne Agee... Hercules Technology (HTGC) upgraded to Buy from Hold at Sandler ONeill... Standard Pacific (SPF) upgraded to Outperform from Market Perform at Raymond James... Yelp (YELP) upgraded to Outperform from Perform at Oppenheimer... Netflix (NFLX) upgraded to Outperform from Perform at Oppenheimer... Pandora (P) upgraded to Outperform from Neutral at Wedbush.
09:34 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:10 EDTMATOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:04 EDTMCKMcKesson announces results of Celesio takeover offer
Subscribe for More Information
08:09 EDTMRKAlnylam's McSwiggen patent upheld in European opposition proceedings
Subscribe for More Information
07:27 EDTMRKAmerican Association of Cancer Research to hold annual meeting
Subscribe for More Information
07:09 EDTNFLXNetflix upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded its rating on Netflix (NFLX) shares to Outperform with a $419 price target citing the recent pullback in shares. Opco sees an attractive risk/reward profile at current share levels.
06:41 EDTNFLXMicrosoft pushes for programming to rival Amazon, Netflix, Bloomberg says
Subscribe for More Information
06:04 EDTMATMattel downgraded to Underperform from Market Perform at BMO Capital
BMO Capital downgraded Mattel citing earnings risk from cyclical declines in Barbie and Hot Wheels, disappointing performance in Max Steel and Ever After High, and deteriorating sales in Monster High. The analyst sees continued deterioration in earnings given weak mature markets, challenges in emerging markets, and lack of sales leverage and cost savings opportunities. Price target lowered to $33 from 40.
April 6, 2014
14:21 EDTNFLXYahoo plans to acquire bigger budget TV programming, WSJ says
Subscribe for More Information
13:37 EDTMRKMerck presents findings on clinical outcomes following treatment with MK-3475
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use